RxDoctor Payments DataLook up a doctor →

Peter Hoagland, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1629059779

Payments from drug & device makers

$241,826in general payments, 2019–2025

Across 385 payments — averaging $628.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accriva Diagnostics Inc.$170K
  • Novartis$24K
  • Boston Scientific$19K
  • Amgen$14K
  • Amarin Pharma, Inc.$6K
  • Boehringer Ingelheim$3K
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$4355%
  • Speaking & faculty fees$2,89531%
  • Food & beverage$5,95563%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$241,826 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$627,381
Medicare patients
733
Services billed
3,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$394,719
EntrestoSacubitril/Valsartan120$194,373
XareltoRivaroxaban124$185,518
JardianceEmpagliflozin73$97,507
FarxigaDapagliflozin Propanediol72$89,902
VascepaIcosapent Ethyl62$38,910
Repatha SureclickEvolocumab33$37,091
Repatha PushtronexEvolocumab19$22,451
Praluent PenAlirocumab14$18,802
NexlizetBempedoic Acid/Ezetimibe16$15,174
Ezetimibe223$9,522
Dofetilide18$7,948
Valsartan200$7,387
Atorvastatin Calcium409$4,394
Rosuvastatin Calcium171$4,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$249$394,719278 claims
NovartisEntresto$23,771$194,373120 claims
Johnson & JohnsonXarelto$179$185,518124 claims
Boehringer IngelheimJardiance$2,953$97,50773 claims
AstraZenecaFarxiga$1,096$89,90272 claims
Esperion Therapeutics, Inc.Nexlizet$108$15,17416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →